<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04696003</url>
  </required_header>
  <id_info>
    <org_study_id>2020-185</org_study_id>
    <nct_id>NCT04696003</nct_id>
  </id_info>
  <brief_title>Treatment of Classic Mid-trimester PPROM by Means of Continuous Amnioinfusion</brief_title>
  <acronym>AmnionFlush</acronym>
  <official_title>Treatment of Classic Mid-trimester Preterm Premature Rupture of Membranes (PPROM) With Oligo/Anhydramnion Between 22/0-26/0 Week of Gestation by Means of Continuous Amnioinfusion: a Multicenter Prospectiv Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: Mid-trimester preterm premature rupture of membranes (PPROM), defined as rupture&#xD;
      of fetal mem-branes prior to 28 weeks' gestation (WG), complicates approximately 0.4-0.7% of&#xD;
      all pregnancies and associated with very high neonatal mortality and morbidity. Antibiotics&#xD;
      have limited success to prevent bacteremia, chorioamnionitis and fetal inflammation because&#xD;
      of reduced placental transport. The repetitive amnioinfusion doesn't work because of&#xD;
      immediately fluid lost after the intervention). The continuous amnioinfusion with Amnion&#xD;
      Flush Solution through the perinatal port system in patients with classic PPROM prolonged the&#xD;
      PPROM-to-delivery interval to 49 days in average by flush out of bacteria and inflammatory&#xD;
      components from the amniotic cavity.&#xD;
&#xD;
      Aim: This multicenter trial tests the effect of continuous amnioinfusion on the neonatal&#xD;
      survival without major morbidities, like severe bronchopulmonary dysplasia, intraventricular&#xD;
      hemorrhage, cystic periventricular leukomalacia and necrotizing enterocolitis.&#xD;
&#xD;
      Design: randomized multicenter controlled trial; two-arm parallel design. Control group: 34&#xD;
      PPROM patients between 22/0 (20/0) -26/0 WG treating with antibiotics and corticosteroids in&#xD;
      according to DGGG guide-lines. In interventional group (n=34) the standard PPROM therapy will&#xD;
      be complemented by &quot;Amnion -Flush&quot; method with the amnioinfusion of artificial amniotic fluid&#xD;
      (Amnion Flush Solution, Serumwerk AG, Germany, 2400 ml/d).&#xD;
&#xD;
      Subjects: Patients with classic PPROM between 22/0-26/0 WG. Expected outcome:The&#xD;
      investigators expect significant reduction of neonatal mortality and morbidity in the&#xD;
      &quot;Amnion-Flush&quot; group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:&#xD;
&#xD;
      Mid-trimester preterm premature rupture of membranes (PPROM), defined as rupture of fetal&#xD;
      mem-branes prior to 28 weeks' gestation (WG), complicates approximately 0.4-0.7% of all&#xD;
      pregnancies and associated with very high neonatal mortality and morbidity. Antibiotics have&#xD;
      limited success to prevent bacteremia, chorioamnionitis and fetal inflammation because of&#xD;
      reduced placental transport. The repetitive amnioinfusion doesn't work because of immediately&#xD;
      fluid lost after the intervention). The continuous amnioinfusion with Amnion Flush Solution&#xD;
      through the perinatal port system in patients with classic PPROM prolonged the&#xD;
      PPROM-to-delivery interval to 49 days in average by flush out of bacteria and inflammatory&#xD;
      components from the amniotic cavity.&#xD;
&#xD;
      Aim: This multicenter trial tests the effect of continuous amnioinfusion on the neonatal&#xD;
      survival without major morbidities, like severe bronchopulmonary dysplasia, intraventricular&#xD;
      hemorrhage, cystic periventricular leukomalacia and necrotizing enterocolitis.&#xD;
&#xD;
      Design: randomized multicenter controlled trial; two-arm parallel design.&#xD;
&#xD;
      Control group:&#xD;
&#xD;
      34 PPROM patients between 22/0 (20/0) -26/0 WG treating with antibiotics and corticosteroids&#xD;
      in according to DGGG guide-lines (7 days Amoxicillin/Clarithromycin therapy or 7 days&#xD;
      Amoxicillin and once Azithromycin 1 g and corticosteroids' RDS prophylaxis).&#xD;
&#xD;
      Experimental group:&#xD;
&#xD;
      34 PPROM patients between 22/0 (20/0) -26/0 WG, continuous amnioinfusion (100 ml/h) in&#xD;
      pregnant women with classic PPROM with oligo-/anhydramnion between 22/0- 26/0 weeks'&#xD;
      gestation and systemic antibiotic therapy (7 days Amoxicil-lin/Clarythromycin or 7 days&#xD;
      Amoxicillin and once Azithromycin 1 g) and corticosteroids' RDS prophylaxis.&#xD;
&#xD;
      Duration of intervention: Maximum till 34/0 weeks of gestation, or preterm delivery if&#xD;
      indicated.&#xD;
&#xD;
      Follow-up per patient: 12 months post-partum. Subjects: Patients with classic PPROM between&#xD;
      22/0 (20/0) -26/0 WG. Primary efficacy endpoint: survival without major morbidity (severe&#xD;
      bron-chopulmonary dysplasia (BPD), and/or grades 3 and 4 intraventricular hemor-rhage (IVH&#xD;
      3-4), and/or cystic periventricular leukomalacia (cPVL), and/or necrotizing enterocolitis&#xD;
      (NEC)) since randomization (event time).&#xD;
&#xD;
      Expected outcome: The envestigators expect significant reduction of neonatal mortality and&#xD;
      morbidity in the &quot;Amnion-Flush&quot; group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized multicenter controlled trial; two-arm parallel design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The neonatal outcome will be evaluated one year after the delivery by the stuff of the University Center of the Clinical Studies.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with bronchopulmonary dysplasia</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number of Participants with severe bronchopulmonary dysplasia (BPD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with intraventricular hemorrhage</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number of Participants with intraventricular hemorrhage (IVH 3-4)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with necrotizing enterocolitis</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number of Participants with necrotizing enterocolitis (NEC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of PPROM to delivery interval</measure>
    <time_frame>up to 15 weeks</time_frame>
    <description>Duration of PPROM to delivbery interval (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gesatational age at delivery</measure>
    <time_frame>34 weeks</time_frame>
    <description>gestational age at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Newborns with FIRS</measure>
    <time_frame>1 week</time_frame>
    <description>Rate of Newborns with FIRS (fetal inflammatory response syndrome) (binary)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Bronchopulmonary Dysplasia</condition>
  <condition>Necrotizing Enterocolitis</condition>
  <condition>Intracranial Hemorrhages</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patients with classic PPROM between 22/0-26/0 weeks' gestation with oligo/anhydramnion with standard conservative treatment (7 days Amoxicillin/Clarithromycin therapy or 7 days Amoxicillin and once Azithromycin 1 g per os, and corticosteroids like Celestan®, Essex Pharma, Munich, Germany) as RDS prophylaxis will represent the control group (DGGG Guideline AWMF 015-025, February 2019, Version 1.0). The diagnosis of the PPROM must be not early than 20/0 weeks' gestation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amnion Flush group (continuous amnioinfusion)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the &quot;Amnion Flush&quot; group additionally to the standard treatment the amniotic cavity will be punctured with a 18 gauge needle under ultrasound control. The intra-amniotic catheter (0.65 mm Diameter, CE 0481, PakuMed GmbH, Essen, Germany) will be placed under local anesthesia with Xylocaine 1% 10 ml. Amnion Flush Solution (CE 0483, Serumwerk AG Bernburg, Germany) will be carried out with an infusion rate of 100 ml/h (2400 ml/d) under periodic ultrasound using the standard i.v. pump. The deepest pool of amniotic ﬂuid should be stabilized by about 4 cm. The ultrasound control will be performed daily. Induction of the labour or c-section at 34/0 week of gestation or earlier if indicated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Continuous amnioinfusion with Amnion Flush Solution through the intraamniotic catheter</intervention_name>
    <description>The amniotic cavity will be punctured with a 18 gauge needle under ultrasound control. The intraamniotic catheter (0.65 mm Diameter, CE 0481, PakuMed GmbH, Essen, Germany) will be placed under local anesthesia with Xylocaine 1% 10 ml. and the amnioinfusion (about 100 ml/h, 2400 ml/day) with artificial amniotic fluid (Amnion Flush Solution, CE 0483, Serumwerk AG Bernburg, Germany) will be carried out with an infusion rate of 100 ml/h under periodic ultrasound using the standard i.v. pump.</description>
    <arm_group_label>Amnion Flush group (continuous amnioinfusion)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Singleton pregnancy (from 22/0 to 26/0 weeks of gestation)&#xD;
&#xD;
          -  Evidence of PPROM from clinical and instrumental investigations&#xD;
&#xD;
          -  Oligo/anhydramnion (&lt; 2 cm deepest amniotic fluid pocket)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  fetal death&#xD;
&#xD;
          -  placental abnormalities&#xD;
&#xD;
          -  labor&#xD;
&#xD;
          -  evidence of major structural or chromosomal abnormalities&#xD;
&#xD;
          -  signs of chorioamnionitis (maternal fever &gt; 38° C and one or more of the following&#xD;
             criteria: uterine tenderness, malodorous vag-inal discharge, maternal leukocytosis &gt;&#xD;
             15000 cells/mm3, maternal tachycardia &gt; 100 beats/min, and fetal heart rate &gt; 160&#xD;
             bpm).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Tchirikov, MD, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>University Clinic of Obstetrics and Prenatal Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Tchirikov, MD, Ph.D.</last_name>
    <phone>-345-57-3250</phone>
    <phone_ext>049</phone_ext>
    <email>michael.tchirikov@uk-halle.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miriam Tchirikov, MD</last_name>
    <phone>-345-57-3250</phone>
    <phone_ext>049</phone_ext>
    <email>miriam.tchirikov@uk-halle.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Martin Luther University, Clinic of Obstetrics and Prenatal Medicine</name>
      <address>
        <city>Halle</city>
        <state>Sachsen Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Tchirikov, MD, Ph.D.</last_name>
      <phone>0345-573250</phone>
      <phone_ext>049</phone_ext>
      <email>michael.tchirikov@uk-halle.de</email>
    </contact>
    <contact_backup>
      <last_name>Christian Haiduk</last_name>
      <phone>0345 557 4920</phone>
      <phone_ext>049</phone_ext>
      <email>Haiduk.Christian@kks-halle.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Tchirikov M, Zhumadilov Z, Winarno AS, Haase R, Buchmann J. Treatment of Preterm Premature Rupture of Membranes with Oligo-/Anhydramnion Colonized by Multiresistant Bacteria with Continuous Amnioinfusion and Antibiotic Administrations through a Subcutaneously Implanted Intrauterine Port System: A Case Report. Fetal Diagn Ther. 2017;42(1):71-76. doi: 10.1159/000438483. Epub 2015 Oct 9.</citation>
    <PMID>26447923</PMID>
  </reference>
  <reference>
    <citation>Tchirikov M, Bapayeva G, Zhumadilov ZSh, Dridi Y, Harnisch R, Herrmann A. Treatment of PPROM with anhydramnion in humans: first experience with different amniotic fluid substitutes for continuous amnioinfusion through a subcutaneously implanted port system. J Perinat Med. 2013 Nov;41(6):657-63. doi: 10.1515/jpm-2012-0296.</citation>
    <PMID>23774012</PMID>
  </reference>
  <results_reference>
    <citation>Tchirikov M, Schlabritz-Loutsevitch N, Maher J, Buchmann J, Naberezhnev Y, Winarno AS, Seliger G. Mid-trimester preterm premature rupture of membranes (PPROM): etiology, diagnosis, classification, international recommendations of treatment options and outcome. J Perinat Med. 2018 Jul 26;46(5):465-488. doi: 10.1515/jpm-2017-0027. Review.</citation>
    <PMID>28710882</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Martin-Luther-Universität Halle-Wittenberg</investigator_affiliation>
    <investigator_full_name>Michael Tchirikov MD, PhD</investigator_full_name>
    <investigator_title>Univ.-Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>PPROM, Amnion Flush Solution, outcome, amnioinfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enterocolitis</mesh_term>
    <mesh_term>Enterocolitis, Necrotizing</mesh_term>
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

